Previous 10 | Next 10 |
Shares of Relay Therapeutics (NASDAQ: RLAY) , a clinical-stage biopharmaceutical company, have risen about 30% since the stock's closing price last Friday. Investors are highly encouraged by interim clinical trial data that suggest the company's new approach to drug development can ...
Gainers: Hyzon Motors HYZN +5%. Avadel Pharmaceuticals (NASDAQ:AVDL) +4%. Allogene Therapeutics (NASDAQ:ALLO) +4%. Latch (NASDAQ:LTCH) +2%. Old National Bancorp (NASDAQ:ONB) +2%. Losers: Xiaobai Maimai (NASDAQ:HX) -4%. Clarus Therapeutics Holdings (NASDAQ:CRXT) -4%. Relay Thera...
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwrit...
M&A headlines provided a key theme in Tuesday's pre-market trading. A host of private-equity firms are reportedly looking at GlaxoSmithKline's (NYSE:GSK) consumer unit. Meanwhile, Signet Jewelers (NYSE:SIG) rallied on a $490M purchase and raised guidance. In other news, Nike (NYSE:NKE) dr...
Gainers: QTRX +18.5%. PROG +3.7%. MTTR +2.6%. KC +2.5%. LFMD +2.2%. Losers: RLAY -8.9%. HX -6.2%. ACHL -3.4%. STLD -2.0%. ARRY -1.9%. For further details see: QTRX, PROG, RLAY and HX among after hours movers
CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced ...
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4) RLY-4008 demonstrated tumor shrinkage in all six pan-FGFR treatment-naïve FGFR2 fusion positi...
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform Preclinically, achieved tumor regressions in vivo with significantly reduced impact on glucose metabolism compared to active site inhibitors RLY-26...
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced that initial clinical data...
Company selected RLY-2608 as PI3Kα mutant inhibitor development candidate and plans to initiate first-in-human study in the first half of 2022 RLY-2608 potently inhibits mutants H1047X, E542X, and E545X, which affect over 100,000 patients annually in the U.S. Rela...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transfo...
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2024 financial res...
2024-04-24 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...